I'll take it as unsaid that you were misquoting me in error.
There are some lay down miseres in life that don't present often LJ.
A blue chip pharma is paying an acceptable price, as judged by the Founder, Board and an Independent expert, for a micro cap which is bouncing along with no cash in the bank, a disappointing trial result and listening to many posters, a BOD and management team whose heart is no longer in it. The arb is 27% for 6 weeks.
If you paid too much for this company, as judged by the offer on the table, then average down and make 27% for the next 6 weeks on your new money. then divert your capital in to a company which has upside without as many challenges.
RAP Price at posting:
11.5¢ Sentiment: Buy Disclosure: Held
